Investments
330Portfolio Exits
98Funds
16Partners & Customers
8Service Providers
3
Want to inform investors similar to Frazier Healthcare Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing Frazier Healthcare Partners
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Frazier Healthcare Partners in 2 CB Insights research briefs, most recently on May 7, 2020.
Latest Frazier Healthcare Partners News
Jan 18, 2023
Free Membership for Qualified Investors and Industry Participants Easily Customize Content to Match Your Investment Preferences Breaking News 24/7/365 Alternative Investment Listings & LeaderBoards Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets,Presentations, Investment Mandates, Video PitchBooks & More! Company Directory AUM Accelerator Program (designed for investment managers) Over 450K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN
Frazier Healthcare Partners Investments
330 Investments
Frazier Healthcare Partners has made 330 investments. Their latest investment was in Alpha-9 Theranostics as part of their Series B on December 12, 2022.
Frazier Healthcare Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/14/2022 | Series B | Alpha-9 Theranostics | $75M | Yes | 6 | |
11/14/2022 | Series B | MBX Biosciences | $115M | No | 10 | |
9/28/2022 | Series A | Sudo Biosciences | $37M | Yes | 10 | |
1/25/2022 | Series B | |||||
11/30/2021 | Series A |
Date | 12/14/2022 | 11/14/2022 | 9/28/2022 | 1/25/2022 | 11/30/2021 |
|---|---|---|---|---|---|
Round | Series B | Series B | Series A | Series B | Series A |
Company | Alpha-9 Theranostics | MBX Biosciences | Sudo Biosciences | ||
Amount | $75M | $115M | $37M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 6 | 10 | 10 |
Frazier Healthcare Partners Portfolio Exits
98 Portfolio Exits
Frazier Healthcare Partners has 98 portfolio exits. Their latest portfolio exit was OHI on December 22, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/22/2022 | Acq - Fin - II | 1 | |||
4/29/2022 | IPO | Public | 5 | ||
12/21/2021 | Acquired | 10 | |||
Date | 12/22/2022 | 4/29/2022 | 12/21/2021 | ||
|---|---|---|---|---|---|
Exit | Acq - Fin - II | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 | 5 | 10 |
Frazier Healthcare Partners Acquisitions
19 Acquisitions
Frazier Healthcare Partners acquired 19 companies. Their latest acquisition was Apollo Intelligence on June 07, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
6/7/2022 | Debt | Acq - Fin | 2 | |||
10/29/2020 | Other | $69.46M | Acq - Fin | 2 | ||
9/22/2020 | Acq - Fin - III | 1 | ||||
5/5/2020 | Series B | |||||
1/22/2020 |
Date | 6/7/2022 | 10/29/2020 | 9/22/2020 | 5/5/2020 | 1/22/2020 |
|---|---|---|---|---|---|
Investment Stage | Debt | Other | Series B | ||
Companies | |||||
Valuation | |||||
Total Funding | $69.46M | ||||
Note | Acq - Fin | Acq - Fin | Acq - Fin - III | ||
Sources | 2 | 2 | 1 |
Frazier Healthcare Partners Fund History
16 Fund Histories
Frazier Healthcare Partners has 16 funds, including Frazier Life Sciences XI.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
3/16/2022 | Frazier Life Sciences XI | $987M | 1 | ||
10/28/2021 | Frazier Life Sciences Public Fund | $830M | 1 | ||
5/27/2021 | Frazier Healthcare Growth Buyout Fund X | $1,400M | 1 | ||
1/16/2020 | Frazier Life Sciences X | ||||
4/10/2018 | Frazier Healthcare Growth Buyout Fund XI |
Closing Date | 3/16/2022 | 10/28/2021 | 5/27/2021 | 1/16/2020 | 4/10/2018 |
|---|---|---|---|---|---|
Fund | Frazier Life Sciences XI | Frazier Life Sciences Public Fund | Frazier Healthcare Growth Buyout Fund X | Frazier Life Sciences X | Frazier Healthcare Growth Buyout Fund XI |
Fund Type | |||||
Status | |||||
Amount | $987M | $830M | $1,400M | ||
Sources | 1 | 1 | 1 |
Frazier Healthcare Partners Partners & Customers
8 Partners and customers
Frazier Healthcare Partners has 8 strategic partners and customers. Frazier Healthcare Partners recently partnered with Pivotal bioVenture Partners China on December 12, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
12/3/2021 | Partner | China | News - Pivotal bioVenture Partners China Announces Formation of SanReno Therapeutics SanReno Therapeutics is a joint venture with an investor syndicate led by Pivotal bioVenture Partners China and Frazier Healthcare Partners to develop , manufacture and commercialize kidney disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan , as well as Singapore , and Chinook Therapeutics , Inc. has granted SanReno Therapeutics exclusive rights to develop and commercialize atrasentan and BION-1301 in Greater China and Singapore . | 1 | |
7/30/2021 | Licensor | ||||
5/16/2019 | Partner | ||||
2/6/2019 | Partner | ||||
12/17/2018 | Partner |
Date | 12/3/2021 | 7/30/2021 | 5/16/2019 | 2/6/2019 | 12/17/2018 |
|---|---|---|---|---|---|
Type | Partner | Licensor | Partner | Partner | Partner |
Business Partner | |||||
Country | China | ||||
News Snippet | News - Pivotal bioVenture Partners China Announces Formation of SanReno Therapeutics SanReno Therapeutics is a joint venture with an investor syndicate led by Pivotal bioVenture Partners China and Frazier Healthcare Partners to develop , manufacture and commercialize kidney disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan , as well as Singapore , and Chinook Therapeutics , Inc. has granted SanReno Therapeutics exclusive rights to develop and commercialize atrasentan and BION-1301 in Greater China and Singapore . | ||||
Sources | 1 |
Frazier Healthcare Partners Service Providers
3 Service Providers
Frazier Healthcare Partners has 3 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - Fin - II | Investment Bank | Financial Advisor, Sole Bookrunner, Sole Lead Arranger | |
Service Provider | |||
|---|---|---|---|
Associated Rounds | Acq - Fin - II | ||
Provider Type | Investment Bank | ||
Service Type | Financial Advisor, Sole Bookrunner, Sole Lead Arranger |
Partnership data by VentureSource
Frazier Healthcare Partners Team
22 Team Members
Frazier Healthcare Partners has 22 team members, including current President, Kelly McCullum.
Name | Work History | Title | Status |
|---|---|---|---|
Kelly McCullum | President | Current | |
Name | Kelly McCullum | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | President | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.